An open engineering platform for academic ADCs and bispecifics
Academic labs find new tumour targets but cannot turn an antibody into an antibody-drug conjugate or a bispecific without licensed linker and payload technology. A shared platform would provide that at no cost for first trials.
A publicly-funded platform holding licences (or developing its own patent-free versions) for linker-payload chemistries, site-specific conjugation, bispecific formats and CAR constructs, offered royalty-free to academic teams for research and first-in-human studies, with commercial terms triggered only on licensing to a company. Paired with GMP manufacturing at translational institutes, this lets academic centres test conjugates against novel or rare-cancer antigens that no company will prioritise. The Structural Genomics Consortium's open chemical probes and the IAVI/Neutralizing Antibody Center model for HIV antibodies are precedents for open engineering infrastructure.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- CompanyTubulis (Gilead)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- PersonElena Garralda
Shares Bispecific antibodies, Antibody-drug conjugate (ADC).
- IdeaTwo-year translational fellowships that pay scientists to develop their own discovery
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- CompanyXencor
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- CompanyAraris Biotech (Taiho)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TermDrug-to-antibody ratio (DAR)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- IdeaA shared compound library that rare cancer researchers can actually use
Shares Secrecy and intellectual property block collaboration, The valley of death between lab and product.